Seres Therapeutics Inc (MCRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.72+1.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MCRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 66.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -76.7% |
Growth built into the price is above our model estimate.
The price assumes 143.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MCRB — debt issuance
Dated 2026-08-04
Entry into a Material Definitive Agreement. Lease Amendment and Termination Agreement On July 31, 2026 (the “Execution Date”), Seres Therapeutics, Inc. (the “Company”) entered into the Third Amendment to Lease and Termination Agreement (the “Termination Agreement”) with BMR-Sidney Research Campus LLC, a Delaware limited liability company (the “Sidney Street Landlord”), the purpose of which is to effect an early termination of one of the Company’s leases, reducing the Company’s ongoing annual…
Why it matters: Funding for the Phase 2 study is crucial for advancing SER-155's development.
Watch forManagement secures funding for the Phase 2 study of SER-155.
Also watch forManagement says there are delays in getting funding for the Phase 2 study.
Why it matters: Funding operations is key for survival. Not having enough money could cause big risks.
Worry ifA new announcement about getting more funding or partnerships was made.
Less concerning ifNo news on funding status shows ongoing financial problems.
Why it matters: A rise in healthcare revenue growth may show a wider recovery. This could help Seres.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Updates on cost savings from lease changes will show financial control. This affects cash flow.
Supportive ifThere is an announcement about lower cash costs from lease changes.
Worry ifThere is no proof of lower costs or more financial pressure from leases.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$318 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $771 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,484 loss on $10,000 · 84.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on lease restructuring will clarify how much operating costs are reduced. This is vital for financial health and cash runway.
Supportive ifThere will be cost savings from lease changes starting in 2027.
Worry ifNo major updates on cost savings or efficiency by Q1 2027.
Why it matters: Starting the Phase 2 study would show commitment to advancing SER-155 for irEC treatment. This could attract partners and funding.
Supportive ifThere is a Phase 2 study for SER-155. This study is for irEC.
Worry ifNo announcement or delay in starting the Phase 2 study for SER-155 in irEC.
Why it matters: Getting this payment would help Seres' cash flow. It will support their ongoing work.
Supportive ifReceipt of the second installment of $12.5 million from Nestlé Health Science on October 1, 2026.
Worry ifFailure to receive the second installment by October 1, 2026.
Why it matters: Safety data will show if SER-155 is safe. This is key for its growth.
Watch forNo serious adverse events reported in the ongoing SER-155 trials.
Also watch forReporting of serious adverse events related to SER-155 in ongoing trials.
Why it matters: Cutting costs through lease changes would help financial stability and extend cash flow.
Supportive ifLook for news on new lease deals or lease terminations that lower costs.
Worry ifNo new lease restructuring announcements by the end of Q4 2026.
Why it matters: Changing this agreement could bring in money and help growth.
Supportive ifA final announcement about new funding terms.
Worry ifNo updates or bad news about the Asset Purchase Agreement.
Why it matters: New clinical data will show how well SER-155 works and its safety. This may affect funding and partnerships.
Watch forGood clinical data shows that patients treated with SER-155 responded well. They did not need immunosuppressive drugs.
Also watch forNegative clinical data shows safety issues or that it does not work well.
Why it matters: New partnerships could provide funding and resources to advance SER-155. This is key for the company's growth strategy.
Watch forA partnership has been announced. This company works on immune checkpoint inhibitors.
Also watch forNo new partnerships have been announced, even though talks are ongoing.